Business Context and Reporting Period
This Form 8-K Current Report was filed by Traws Pharma, Inc. on July 16, 2024. The registrant is a Delaware corporation with its principal executive offices in Newtown, PA. The company's common stock trades on The Nasdaq Stock Market LLC under the symbol TRAW. The filing primarily addresses a change in the company's independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide specific financial data regarding revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a periodic financial statement.
Material Changes
- Change in Certifying Accountant: On July 16, 2024, the Audit Committee engaged KPMG LLP as the new independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Consultation History: The Company confirmed that during the fiscal years ended December 31, 2023 and 2022, and the interim period through July 16, 2024, it did not consult with KPMG regarding accounting principles, audit opinions, or any matters constituting a "disagreement" or "reportable event."
Guidance, Outlook, and Risks
The filing does not contain management guidance, future outlook, or specific risk factors beyond the standard disclosure of the accountant change. The Company has requested a letter from the former auditor, Ernst and Young LLP, confirming agreement with the statements regarding the lack of disagreements or reportable events. This letter, dated July 19, 2024, is filed as Exhibit 16.1.
Investor Verification Checklist
- Verify the effective date of the transition from Ernst and Young LLP to KPMG LLP.
- Review Exhibit 16.1 (Letter from Ernst and Young LLP) to confirm no undisclosed disagreements or reportable events occurred during the prior engagement.
- Monitor upcoming filings (e.g., 10-Q or 10-K) for the first financial statements audited by KPMG.